Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Dapagliflozin boosts erythropoiesis, curbs hepcidin

23 Mar 2020

A new study has found that dapagliflozin therapy increases erythropoiesis and haematocrit by suppressing hepcidin and modulating other iron regulatory proteins.

Fifty-two obese patients with type 2 diabetes (T2D) were included in this prospective, randomized and placebo-controlled study at a single endocrinology centre. Patients were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 weeks. The investigators collected blood samples before and after treatment and prepared serum, plasma and mononuclear cells (MNC).

Treatment with dapagliflozin resulted in a significant decrease in HbA1c and a significant increase in haemoglobin concentration and haematocrit. Circulating hepcidin and ferritin concentrations significantly decreased with dapagliflozin treatment, while levels of the hepcidin inhibitor, erythroferrone, increased; a transient increase in erythropoietin occurred as well.

Dapagliflozin also increased plasma transferrin levels and expression of transferrin receptors 1 and 2 in MNC. No change was observed in the expression of the iron cellular transporter, ferroportin.

In addition, dapagliflozin treatment led to a reduction in hypoxia-induced factor-1α expression in MNC and a heightened expression of its inhibitor, prolyl hydroxylase-2.

In the placebo group, no significant changes were seen in any of these indices.

“Dapagliflozin and other SGLT2 inhibitors are known to increase haematocrit, possibly due to its diuretic effects and haemoconcentration,” the investigators said.

T2D is a proinflammatory state and hepcidin, which is a known suppressor of erythropoiesis, is elevated in proinflammatory states, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.